January 3, 2024 News by Marisa Wexler, MS MS activity not likely to be affected by dairy or gluten foods, study finds An analysis of data covering nearly 200 people with multiple sclerosis (MS) found no association between dairy or gluten consumption and MS disease activity. While some specific diets for MS tend to restrict gluten and/or dairy, this study found that people who ate these dietary products were as…
October 30, 2023 News by Marisa Wexler, MS NEDA 3 and 4 ‘hard to achieve’ with relapsing MS, real-world study finds Achieving NEDA ā no evidence of disease activity ā after two years of treatment was not common among people with relapsing-remitting multiple sclerosis (RRMS) at a center in Italy. NEDA more often was reached, however, when researchers didn’t include the first few months of treatment in their analysis, suggesting…
August 7, 2023 News by Andrea Lobo, PhD Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3 Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced patients’ relapse rates and the development of new lesions while keeping disability stable over two years, according to a real-world study in Kuwait. Among patients who completed the two courses…
June 28, 2022 News by Marisa Wexler, MS No Disease Activity After 4 Years for Nearly 80% of Patients on Kesimpta People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four years were about four times more likely to have no evidence of disease activity than those initially on Aubagio (teriflunomide), according to updated data from the ASCLEPIOS and ALITHIOS…
February 3, 2022 News by Marisa Wexler, MS Self-injectable Therapies Tied to No Disease in 50% of Patients at 2 Years More than half of multiple sclerosis (MS) patients treated with self-injectable therapies ā namely, glatiramer acetate, marketed as Copaxone, among others, or any of a host of interferons ā showed no evidence of disease activity after two years, according to a study out of Turkey. Among patients treated for…
September 2, 2021 News by Steve Bryson, PhD Combo of Biomarkers Predict Future Disease Activity In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. āOur findings encourage the application of both sNfL and retinal…
May 29, 2020 News by Joana Carvalho, PhD Ofatumumab Lowers B-cell Counts and Helps Relapsing MS Patients Reach NEDA, Data Show Ofatumumab (OMB157) elicits a strong and fast reduction in the levels of circulating immune cells in people with relapsing forms of multiple sclerosis (MS), effectively helping to stop disease activity, according to new data from the Phase 2 APLIOS trial. The medication was also found to be more…
November 1, 2019 News by Ana Pena PhD Interferons Superior to Glatiramer Acetate, and Tysabri More Effective than Gilenya for RRMS, Real-world Study Finds Interferon therapy (brand names Avonex, Betaseron, and others) is more effective than glatiramer acetate (sold as Copaxone, Glatopa and other generics) for reducing relapses…
July 24, 2018 News by Ana Pena PhD Cerebrospinal Fluid Neurofilament Predicts CIS and RRMS Progression, Study Contends Cerebrospinal fluid levels of neurofilament light chain, a protein associated with nerve cell damage, can predict disease progression in people with clinical isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS), a Swedish study found. Higher levels…
July 11, 2018 News by Jose Marques Lopes, PhD Rate of Brain Volume Loss Not Adequate as Marker of Treatment Effectiveness in MS Patients, Study Reports Brain volume loss takes place at a faster rateĀ in the first five years of multiple sclerosis than later in disease course, researchers report in a study that calls for scientists to “reconsider” ā for this and related reasons ā proposals to use volume loss as a measure of treatment efficacy…
June 13, 2018 News by Vijaya Iyer, PhD Effectiveness of Gilenya and Tecfidera Compared in Real-World Study in Italy Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are equally effective as first-line treatments in people with relapsing-remittingĀ multiple sclerosis (RRMS), but Gilenya may be of slightly more benefit to those who switch from a previous injectable therapy, according to a real-world study of patients in Italy. The study, “…
April 25, 2017 News by Patricia Silva, PhD Real-world Data of Gilenya Treatment Validates Slowed Brain Shrinkage as Disease Progression Measure A real-world study of Gilenya (fingolimod) in relapsing multiple sclerosis (MS) confirms benefits of the treatment seen in clinical trials. The Novartis-sponsored study also demonstrated that measures of brain shrinkage can be used in a clinical setting to evaluate disease progression. The data, presented at theĀ American Academy of…